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Abstract
Biliary tract carcinomas are aggressive tumors that arise from epithelial cells of bile ducts. 
They present several difficulties in their clinical management. A late initial diagnosis (fre-
quently in the form of locally advanced disease), jaundice, cholangitis, or poor perfor-
mance status of patients are some of the medical issues that arise in this setting. Another 
clinical limitation is the lack of robust evidence for many of the standard procedures in 
this particular scenario. Biliary tumors are lethal tumors, and most of them present in the 
form of advanced disease or during late evolution. However, we are witnessing some 
exciting changes in clinical management of tumors of the biliary tract, such as the devel-
opment of new radiological techniques and novel interventional radiology procedures, 
the emergence of new radiotherapy modalities, the establishment of standardized che-
motherapy regimens, the advance in molecular knowledge, and the development of new 
treatments directed against therapeutic targets. On the other hand, the most important 
step for advancing the treatment of these complex diseases is the appearance of multi-
disciplinary management teams integrating qualified specialists to resolve appropriate 
treatment challenges. In this chapter, we summarize the most relevant advances in clini-
cal management and new oncologic treatment in biliary tract carcinomas.
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1. Introduction
Biliary tract carcinomas are rare and highly lethal tumors that arise from epithelial cells of bile 
ducts. Bile duct carcinomas are divided into extrahepatic and intrahepatic carcinomas, and 
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most of them are locally advanced tumors at presentation. Intrahepatic tumors were classified 
typically as primary liver cancer, while extrahepatic tumors were traditionally divided into 
cancers of the gallbladder, the extrahepatic ducts, and the ampulla of Vater.
Usually, the term of cholangiocarcinoma has been used to describe bile duct cancers arising in 
the intrahepatic, perihilar or distal (extrahepatic) biliary tree, exclusive of the gallbladder, or 
ampulla of Vater. In general, perihilar disease represents 50%, distal disease 40%, and intra-
hepatic disease less than 10% of biliary tract cases [1].
Clinically, bile duct tumors can manifest different clinical presentations, mainly on the basis of 
the initial growth site. Thus, tumors of the intrahepatic biliary tract appear as locally advanced 
hepatic mass with or without satellite lesions, and mimic isolated metastases from the other 
primary sites, or they can pose a differential diagnosis with the other primary hepatic tumors, 
mainly with hepatocellular carcinoma (HCC). Gallbladder tumors can be difficult to differen-
tiate from abscesses or be a part of an atypical choledocholithiasis evolution. Proximal biliary 
tumors may be morphologically similar to pancreatic head cancer and cholangiocarcinomas 
distal to duodenal tumors. The profile of serum tumor markers (especially CA 19.9), the mor-
phology, and especially the pathological anatomy data are the key to its final diagnosis.
Incidence data worldwide are difficult to evaluate because intrahepatic and extrahepatic tumors 
are included in separate categories. Intrahepatic bile duct carcinomas are usually assigned as 
primary liver tumors, while extrahepatic duct carcinomas are independent entities rather than 
grouped gallbladder cancers. In the United States, gallbladder and other extrahepatic bile duct 
tumors represent 12,190 estimated new cases and 3790 estimated deaths for 2018 [2]. Some stud-
ies suggest that only 15% of biliary tree tumors are intrahepatic cholangiocarcinomas [3], a min-
imal proportion of 42,000 new cases and 32,000 deaths of primary liver tumors in this period.
Bile duct tumors in recent years have undergone several relevant modifications regarding 
their staging. Importantly, the newest version of the American Joint Committee on Cancer 
(AJCC)/Union for International Cancer Control (UICC) Cancer Staging Manual differs in their 
definitions of T stage and the prognostic stage groupings [4]. Some of these changes in this 
newest version (2017) improved the prognostic stratification of the TNM staging system [5] 
and presented notable implications for interpretations and comparison of outcomes from tri-
als and retrospective series that used older TNM staging criteria [6].
Tumors of the bile duct are entities that present many limitations in their clinical manage-
ment. Globally, cholangiocarcinomas present with a marked poor prognosis and several dif-
ficulties in their initial diagnosis, frequently in the form of locally advanced disease, jaundice, 
cholangitis, or poor performance status of patients. On the other hand, the need for sophisti-
cated diagnostic methods often includes the need for insertion of biliary stents that normalize 
bile flow, which increases cost and risk of severe complications. Similarly, surgery in cases 
of localized disease presents a relevant postsurgical morbidity and mortality. The manage-
ment of locally advanced tumors is poorly defined, while disseminated tumors have a lack 
of effective treatments. For all of these reasons, bile duct tumors are a clinical challenge that 
requires specialized centers for proper management. The creation of multidisciplinary teams 
is mandatory to optimize the knowledge of each specialist in each field.
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Treatment of bile duct tumors is based on localization (intrahepatic, gallbladder, distal, peri-
hilar, or proximal tumor), staging (potentially resectable, locally advanced—unresectable 
and advanced tumors), and the patient’s general state at diagnosis (including liver func-
tion). Currently, we lack prognostic or predictive biomarkers of response whose optimiz-
ing decisions in clinical management of these tumors. Efforts should be directed toward 
improving and optimizing the clinical guidelines with which relevant clinical decisions are 
made.
In this chapter, we summarize the most relevant advances in the clinical management and the 
treatment of bile duct carcinomas. In recent years, there has been a great variety of novelties 
in diagnosis management (especially new radiological techniques, vascular radiology, and 
nuclear medicine) and therapeutic (including the best knowledge of the molecular biology 
of cholangiocarcinoma and relevant advances in immunotherapy, liquid biopsy, or targeted 
therapies) that we will review in the following sections.
2. New radiological techniques
2.1. Abdominal ultrasound
Ultrasound is the initial modality of choice to evaluate the liver and biliary system frequently 
due to decreased associated cost, quick access, and no radiation. The assessment of biliary ductal 
dilatation is excellent with standard ultrasound given its satisfactory sensitivity of 85–95% [7]. 
However, just as clinically indicated, it is difficult to distinguish between cholestatic jaundice 
caused by benign entities and malignant etiologies, and standard ultrasound also suffers from 
some limitations. In the setting of a dilated biliary system and clinical suspicion for malig-
nancy, the sonographer must perform a detailed scan of the liver parenchyma. Unfortunately, 
even with a detailed examination, standard ultrasound examination only results in correct 
diagnoses of benign lesions in 26–35% of cases and 28–39% in malignant lesions [8]. Contrast-
enhanced ultrasound imaging thus represents a breakthrough in increased detection of hepa-
tobiliary malignancy. With contrast-enhanced ultrasound, detection of malignant lesions is 
comparable and sometimes superior to those of contrast-enhanced computed tomography or 
magnetic resonance imaging, with sensitivity and specificity at 88 and 81%, respectively [9]. 
Notably, this requires advanced equipment fitted with a low-mechanical index option and 
pulse-inversion harmonic imaging in order to not degrade the microbubbles of the intrave-
nous contrast agent. A contrast-enhanced examination typically utilizes three phases of con-
trast including arterial (early) phase at 15–35 s post injection, portal phase at 35–90 s, and 
delayed venous phase at 90–240 s [7]. A final limitation of ultrasound is the fact that it is 
very experience-dependent when compared with CT and MRI examinations, thus requir-
ing a well-trained ultrasonographer for optimal results. Ultrasound is also not as accurate 
as CT and MRI with regard to the estimation of tumor spread and tumor resectability [10]. 
Thus, ultrasound is often used for initial evaluation to determine the next appropriate imag-
ing modality of choice.
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Endoscopic retrograde cholangiopancreatography (ERCP) was previously the standard estab-
lished procedure for working-up patients with obstructive jaundice. Given its invasive char-
acteristics and inherent complication rate of 3–9% and mortality of 0.2–0.5%, other modalities 
such as MRCP have become the initial test of choice [11]. ERCP is now almost exclusively 
used in a therapeutic role and not in initial diagnosis. However, when ERCP is used, endo-
scopic ultrasound (EUS) can be used as an adjunct procedure to detect and stage periampul-
lary neoplasm and for ultrasound-guided fine needle aspiration.
2.2. Computed tomography
Although utilizing radiation, computed tomography (CT) is an excellent modality to assess 
the biliary tract given its quick acquisition and thus patient tolerance. Contrast-enhanced CT 
is highly accurate in the detection of biliary ductal dilatation and is easily used in this set-
ting of a dilated biliary system. The normal common bile duct and common hepatic duct 
diameter are generally less than 7 mm with imperceptible or barely visible wall at the time 
of CT imaging [12]. The normal intrahepatic ducts should only be faintly seen at the time 
of contrast-enhanced CT imaging; if they are visualized, further search should be initiated 
as the differential includes proximal benign stricture, inflammation, biliary tract stones, or 
neoplasm. Distinguishing benign from malignant strictures can often be difficult, but, in 
general, malignant neoplasms demonstrate irregular, eccentric shouldering at the transition 
point from normal caliber to dilated ducts [12]. Benign strictures often demonstrate smooth, 
uniform narrowing as the ductal system transitions from normal caliber to dilated ducts [6]. 
Once biliary neoplasm is suspected, a multiphase contrast-enhanced CT approach is the key 
as cholangiocarcinoma is best discovered on delayed phase imaging (10–20 min, for example) 
with retention of contrast material in 40% of cholangiocarcinomas when compared with the 
normal surrounding liver parenchyma [12].
One of the major goals of imaging, particularly with CT, is to establish the presence or absence 
of satellite nodules or distant metastases, also identifying the relationship of the tumor to 
the biliary tree, hepatic vasculature, and the inferior vena cava [13]. CT is also useful to per-
form volumetric assessment, which allows evaluation for viable potential liver remnants if 
patients are considered for surgical resection. Extrahepatic disease evaluation is also impor-
tantly evaluated, often with a contrast-enhanced CT examination of the chest, abdomen, and 
pelvis. Limitations of CT include underestimation of longitudinal and proximal extent of the 
tumor and a sensitivity of only 54% for regional adenopathy. Other limitations include streak 
artifact and secondary inflammatory changes, which occur in the setting of patients with bili-
ary stents [13].
2.3. Magnetic resonance imaging
Magnetic resonance imaging (MRI) is an excellent modality for the assessment of the biliary 
system due to its lack of ionizing radiation and excellent contrast resolution. MRCP is consid-
ered the radiologic modality of choice in the evaluation of patients with suspected cholangio-
carcinoma given its accurate ability to map the biliary tree without requiring instrumentation 
[13]. MRCP takes advantage of the relatively high-signal intensity of static fluids in the biliary 
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tract with heavily T2-weighted sequences, resulting in excellent contrast given the associated 
low signal of the remaining background tissues [12]. It achieves better evaluation of periph-
eral ductal involvement in cholangiocarcinoma given that an obstructing tumor will often not 
allow the more peripheral ducts to be adequately be filled during ERCP [13].
The previously long-imaging times for MRCP have been diminished by the use of short-
breath hold T2-weighted acquisitions, parallel imaging, and sophisticated respiratory trig-
gering mechanisms [12]. Utilizing a 1.5 Tesla strength magnet scanner or greater and modern 
multichannel surface coil technology also shortens the imaging times. T1-weighted images 
with and without gadolinium contrast are performed as well, particularly in the staging of 
biliary malignancies. 3D isotropic MRCP is often utilized to improve visualization of the 
intrahepatic bile ducts, allowing thinner sections without intersection gaps and the ability to 
manipulate the images into any projection for surgical planning [12].
MRI hepatobiliary-specific contrast agents are a particular advantage for imaging the biliary 
system. These initially distribute in the extracellular fluid compartment, thus providing ini-
tial excellent vascular evaluation during the arterial and portal venous phases. They are also 
actively taken up by the hepatocytes and excreted into the bile, providing excellent imaging 
of the biliary system on more delayed imaging. These agents are separated into two main 
categories: manganese-based (mangafodipir trisodium, Teslascan®) and gadolinium-based 
(gadobenate dimeglumine, MultiHance® and gadoxetic acid, Primovist® in Europe and 
Eovist® in the United States) agents [13].
2.4. Interventional radiology
In cases of malignant biliary obstruction, interventional management may be indicated. 
Percutaneous biliary drainage can be performed to decrease serum bilirubin levels, which 
may facilitate medical therapy, chemotherapy, or possible surgical interventions. However, 
not all patients may be good candidates for this procedure and preprocedural total serum bili-
rubin levels, international normalized ratio (INR) and the degree of biliary drainage should 
be utilized as prognostic factors for subsequent patient selection [14].
Before considering biliary intervention, appropriate cross-sectional imaging should be per-
formed such as thin-slice computer tomography (CT) and magnetic resonance (MR) imaging 
with MR cholangiopancreatography (MRCP) protocol. Low bile duct obstructions can fre-
quently be managed by using a single catheter or stent across the obstruction through endo-
scopic retrograde cholangiopancreatography (ERCP). Conversely, high bile duct obstruction 
involving the confluence or more proximal ducts may not be amenable to such a procedure. 
Depending on the unique circumstances of each case, interventional procedures such as per-
cutaneous cholangiography, percutaneous transhepatic biliary drainage (PTBD), stent place-
ment, and bile duct biopsy may need to be performed [14].
2.5. Nuclear medicine in biliary tree tumors
Positron emission tomography (PET) appearance in the clinical practice scenario has been 
revealed as a usefulness advancement in the staging and clinical management of a wide 
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 variety of tumors, such as colon cancer, lung cancer, melanoma, and many others. However, 
the role of PET in bile duct tumors is not well defined. Clinical studies focused on the value 
of the extension study in potentially resectable tumors, both intrahepatic cholangiocarcinoma 
and cholangiocarcinoma, gallbladder cancer or common bile duct cancer [15, 16]. Preliminary 
studies point to some utility in the neoadjuvant setting. It seems to be a technique especially 
useful in the detection of affected lymph nodes. The value of the high SUV-max glucose uptake 
is also associated with an unfavorable prognostic value [15]. Local or distant tumor relapse 
detection by PET during clinical surveillance after radical resection has been described [17], 
but the value for this setting needs to be developed (Figure 1).
3. Surgical approaches
3.1. Management of resectable bile duct carcinomas
Surgical resection of bile duct tumors is the only curative treatment in these tumors. Distal 
cholangiocarcinomas have the highest rates of resection, while proximal tumors have the low-
est rates (particularly, perihilar neoplasms) [16–18]. Resection rates of distal, intrahepatic, and 
perihilar lesions are 91, 60, and 56%, respectively [19], in some studies. Even in patients who 
undergo potentially curative resection, margins free of tumor involvement can be obtained 
in only 20–40% of distal tumors and 50% of distal tumors [20]. A tumor-free proximal margin 
of at least 5 mm is necessary, so the series presented with these criteria are markedly low; 
this is an important issue because resection with margins is the only curative procedure [21]. 
Therefore, although surgical resection remains the gold standard for this disease, it is not so 
frequent to obtain long-term survival due to frequent postoperative recurrences [22, 23].
The main clinical requirements for resectability are absence of distant hepatic metastases or 
disseminated disease, absence of retropancreatic node metastases involvement, absence of 
Figure 1. Positron emission tomography. Biliary tract relapse on a drainage sinus scar.
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portal vein invasion or major hepatic artery (although in many oncological centers, where our 
institution, en-bloc resection with vascular recovery can be considered), and the absence of 
invasion of adjacent extrahepatic organs [24].
Patients with positive margins after resection or regional lymph nodes should have been pre-
pared for adjuvant chemotherapy based on 5FU as well as radiation. Unfortunately, no ran-
domized trials that support a standard regimen are defined. People with negative margins 
after surgery and negative involvement of the lymph nodes can be observed or treated with 
adjuvant strategies [25]. Radiotherapy and postoperative chemotherapy as clinical options in 
this setting are discussed in the following sections.
3.2. Computer-assisted surgery
Robotic surgery or robotically assisted surgery refers to technological developments in base 
to robotic systems aiding the surgical interventions, overcoming the surgical limitations, and 
enhancing the capabilities of surgeons performing traditional surgery. There are several theo-
retical advantages of robotic surgery: possibility of surgeries under remote control, improve-
ment in precision procedures, minimum invasion, and lower postoperative morbidity.
The use of robotic surgery in tumors of the bile duct is currently considered to be nonstan-
dard of care procedure. We can mention some theoretical limitations: surgical procedures 
need optimal software services and marked efforts for coordination among other specialist 
(i.e., pathological evaluation). Other limitations could be the high cost and the complexity of 
surgeon’s training.
3.3. Orthotopic liver transplantation
Orthotopic liver transplantation is an option that should be considered, exceptionally, gener-
ally in highly selected proximal cholangiocarcinomas in combination with neoadjuvant treat-
ment. Only a minority of patients will result in their eligibility, due to the restrictive criteria 
for their inclusion and the availability of liver transplant programs [26].
Selection criteria include the presence of a tumor without the possibility of a wide margin 
of resection, a good liver function, and the absence of metastasis (intra- or extrahepatic). 
These patients frequently begin their treatment with EBRT with concurrent chemotherapy 
1–3 months; during a period, it is possible to demonstrate the absence of rapid systemic dis-
semination. Some clinical series offers remarkable survival rates [27]. However, its complex 
management and the restrictive conditions for participation make difficult to interpret the 
real benefit of this technique in overall management of bile duct patients.
3.4. Follow-up after resection and diagnosis of loco-regional relapse
No clear guidelines exist for follow-up after surgery in this particular tumor type. A reason-
able approach seems to be physical exam with routine laboratory tests every 3–4 months for 
the first 3 years post-surgery and subsequently at longer intervals of 6 months until Year 
5. The role of CA 19-9 level in surveillance is not clear, but persistently, rising levels often 
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precede radiological evidence of recurrence by a number of months. Therefore, this marker 
has been routinely incorporated in follow-up schemas. Which imaging tests to be performed 
is a topic that has not been specifically addressed in prospective trials, although CT scans 
of the abdomen every 6 months for 2–3 years after surgery are probably the most common 
approach in routine practice. However, depending on the case presented, CT and abdomi-
nal ultrasound are often not sufficient to detect loco-regional relapses, which could be easily 
determined on MRI and PET.
While recurrence is mostly loco-regional in the majority of proximal tumors, distal cholangio-
carcinomas recur frequently at distant sites including the liver, peritoneum, and lung [28, 29]. 
Like pancreatic, gallbladder, and hepatocellular cancers, adenocarcinomas of the bile duct 
have a predisposition to seed and can recur in needle biopsy tracts, abdominal wall incision 
wounds, and the peritoneal cavity, and therefore, it is recommended to be especially careful 
in the physical exams of each follow-up visit [17].
3.5. Clinical management of loco-regional relapse
The ideal management of loco-regional relapse still remains undefined. No prospective data 
exist to set definitive recommendations about the optimum treatment after a curative resec-
tion of adenocarcinoma of the extrahepatic bile ducts. Currently, decisions are made based on 
different clinical parameters that have been established as prognostic factors in retrospective 
series, such as tumor grade, surgical margins, or lymph node involvement.
Surgery is generally not indicated for recurrent bile duct adenocarcinoma due largely to the 
location of recurrence, technical difficulty, frequent distant metastases, and aggressiveness. 
However, in patients with prolonged relapse-free interval and favorable location, surgery 
should be an option to consider [17]. Radiotherapy and systemic chemotherapy will be com-
mented in the following sections.
4. Radiotherapy
4.1. Radiation techniques
Historically, radiotherapy was used in patients with locally unresectable advanced bile duct 
tumors as a palliative treatment in search of local control. However, a measurable benefit of 
radiotherapy treatment in terms of survival in this setting has not been well established [30, 
31] because of a small size and retrospective design of the studies.
New advances in technology and improvements in safety and effectiveness may have resulted 
in some benefit using radiotherapy in locally or locally advanced disease. In addition, the 
improvement in imaging techniques has allowed a more precise planning in the treatment 
of upper gastrointestinal tumors. Specifically, in the last decade, treatments have been opti-
mized based on the new EBRTs, such as 3D conformational radiotherapy (3D-CRT) and inten-
sity-modulated radiotherapy (IMRT). IMRT uses computer-generated images to evaluate the 
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size and shape of the tumor mass, generating different intensities of radiation in base to a 
multiple-angle emission, reducing damage of normal tissues near the tumor.
Studies with accelerated or hypofractionated regimens (i.e., stereotaxic body radiation ther-
apy—SBRT) have been tested in cholangiocarcinoma. SBRT is defined as an external beam 
radiotherapy method used to deliver a high dose of radiation therapy to an extracranial 
target using single or small number of fractions. Those treatments have also been tested 
in patients in the adjuvant setting. However, the difficulty in grouping cases in large and 
comparative clinical trials is a limitation to obtain definitive conclusions from standardized 
procedures.
4.2. Adjuvant and neoadjuvant therapy
At present, the role of neoadjuvant treatment prior to surgical resection is considered experi-
mental. No comparative study has shown a survival benefit or an improvement in resectability 
in this setting. Safety data are not well defined. Neoadjuvant therapy in cholangiocarcinoma 
is a field open to research. The theoretical basis of neoadjuvant treatment offers several attrac-
tive advantages in the clinical management of bile duct tumors. Bile duct carcinomas present a 
high local recurrence rate (even in the context of disease-free surgical margins) and frequently 
preset systemic metastases. Neoadjuvant treatment would allow a theoretical biological con-
trol of the initial micrometastases, a “screening” of the responding patients with a selection of 
patients who would rapidly progress to treatment. Finally, the pathological evaluation of the 
tumor piece after the response to the preoperative treatment could be an excellent prognostic 
marker of the disease, as it happens in the majority of tumors where neoadjuvant treatments 
are used in a habitual way, as in rectal cancer.
On the other hand, the role of postoperative radiotherapy or chemoradiotherapy treatment 
versus chemotherapy alone in patients with resection of bile duct tumors has not been clearly 
defined. In general, preliminary studies offer hopeful results, generally with complementary 
radiotherapy compilation with single-agent therapies. The same considerations should be 
made with intraoperative radiotherapy.
4.3. Therapy for locally advanced disease
Locally advanced bile duct cancer is especially difficult to treat. In many cases, conclu-
sions are based on studies that grouped patients with locally advanced adenocarcinoma 
of the pancreas. Globally, locally advanced bile duct tumors are treated in a similar way. 
Locally advanced unresectable tumors, especially symptomatic masses, can benefit from 
palliative EBRT. Usually, the treatment is combined simultaneously with single-agent 
chemotherapy (5-fluouracil, capecitabine). Treatment is usually continued either after the 
end of treatment or after the progression of disease with palliative chemotherapy (see next 
section).
Currently, the optimal sequence of treatment in locally advanced disease is unknown: che-
motherapy as a first step (also called “induction chemotherapy”) and then radiotherapy with 
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or without concomitant chemotherapy, or radical radiotherapy, or initial radical chemora-
diotherapy. Neither is known the real therapeutic value of surgery after radical radiotherapy 
treatment, and what is the contribution of maintenance chemotherapy in this setting. All these 
questions must be answered with studies during the following years.
5. Chemotherapy
5.1. Adjuvant chemotherapy
Chemotherapy administration after resection of bile duct tumors is controversial. The evi-
dence of benefit in intrahepatic tumors is very limited. The most important studies include 
tumors of the extrahepatic bile duct along with pancreatic cancer and use of single-agent che-
motherapy schemes (5′fluouracil plus leucovorin, capecitabine, gemcitabine) with a marginal 
or no significant benefit.
At the present time, after complete curative surgical resection, clinical options are observed with-
out treatment, chemotherapy (usually with single-agent chemotherapy as fluoropyrimidines or 
gemcitabine for 4–6 months) or chemoradiotherapy (discussed in detail in the next section). The 
results of meta-analysis are conflicting, although patients with node-positive and margin-pos-
itive tumors seem to benefit from treatment with chemotherapy alone or chemoradiotherapy.
5.2. Hepatic artery-based therapies
The rationale of hepatic artery-based therapies is based on the knowledge of the blood flow in 
the liver parenchyma, which is made from the hepatic artery rather than the portal vein. Thus, 
selective catheterization may be performed with the infusion of particles with embolization 
capacity or with cytotoxic chemotherapy infusions into the branch of the hepatic artery that 
feeds the tumor mass (TACE—transarterial embolization). This technique has had a broad 
development in hepatocellular carcinoma (HCC) and is an option to be considered in intrahe-
patic cholangiocarcinomas, although with less evidence. The administration of radioisotopes 
is also well defined in HCC. At present, there are no comparative studies among all the differ-
ent procedures and techniques.
5.3. Chemotherapy in advanced disease
Systemic chemotherapy provides a modest benefit in the treatment of advanced biliary tract 
carcinomas. At present, cancer of the bile duct is considered an incurable and progressive dis-
ease with few cases whose median survival is greater than 1 year. There is a wide variety of 
chemotherapy treatments for advanced disease. The different combinations try to adapt to a 
great variety of factors such as different locations, presence or absence of previous treatments, 
performance status condition of the patient, and the remaining liver function.
Most of the drugs used in this setting are commonly used in other tumors of the upper gastro-
intestinal tract and have some activity on these tumors: gemcitabine, fluoropyrimidines (i.e., 
combinations of 5′fluouracil and leucovorin, capecitabine), platinums (usually oxaliplatin), 
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irinotecan, and anthracyclines. In general, single-agent therapy is usually used for people 
with poor prognosis or poor performance status, while those of good performance status are 
usually treated with chemotherapy combinations.
The most commonly used treatment is the combination of gemcitabine plus cisplatin. The 
treatment has shown a superior overall survival [32] in comparison to treatment with single-
agent gemcitabine (11.7 versus 8.1 months) with an acceptable toxicity profile. However, the 
treatment is not compared with other combinations, also active. Randomized trials will be 
necessary to determine if this is the standard regime.
Second-line treatment lacks robust evidence. In routine clinical practice, progression to 
gemcitabine-based treatment is usually treated with fluoropyrimidine-based chemotherapy 
(oxaliplatin plus leucovorin/5-fluouracil, the FOLFOX regimen).
Initially, any patient with locally advanced incurable bile duct tumors or disseminated tumors 
should be considered for entry into a clinical trial. Within the standard choice, this has to be 
a priority, due to the poor prognosis and the lack of curative treatments in this setting. The 
possibility of genomic sequencing is a fact, and many of the major oncological treatment cen-
ters in the world are initially offering the possibility of such studies within the usual clinical 
practice. Unfortunately, at the present time, there are no specific treatments available for any 
molecular target in the bile duct in routine clinical practice; in addition, some targets have 
been tested in other biologically similar tumors but not in biliary tumors. However, not all the 
entire theoretical therapeutic targets have associated a new molecule or drug in development. 
Despite all these, the need for researchers, physicians, and patients to initiate innovative stud-
ies to improve the prognosis of these tumors is mandatory.
6. Targeted therapy
6.1. Molecular basis
Bile duct carcinoma is one of the most interesting gastrointestinal tumors in terms of genomic 
alterations, as it has been shown in different publications since 2013. However, results of 
targeted therapy for these alterations have been quite disappointing. Compared to other gas-
trointestinal malignancies such as gastric or colorectal carcinoma, no targeted drug has yet 
been approved in cholangiocarcinoma. Despite these poor results, some promising drugs are 
now being evaluated targeting different aberrations observed when whole exome sequencing 
is performed. It is remarkable that bile duct carcinoma should not be considered as a unique 
disease. Intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gallbladder 
carcinoma have a different molecular landscape, and this could explain the low rate of success 
of targeted therapy in these carcinomas.
One of the most relevant analyses in this field [33] based on a whole exome sequencing of 260 
tumors from the biliary tract surprisingly revealed that almost 40% of cases harbored targe-
table genetic alterations comprising a total of 32 genes. Moreover, these genetic alterations 
differ among the different locations, as summarized in Table 1. A total of 137 intrahepatic 
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cholangiocarcinomas, 74 extrahepatic cholangiocarcinomas, and 28 gallbladder tumors were 
analyzed. Main alterations can be classified under five different modules: MAPK pathway 
(RAS, BRAF, EGFR, ERBB2, FGFR, and PTEN), TFG-β pathway (TGF-B, SMAD4, and ARID), 
TP53 pathway (TP53, ATM, and MDM2), cell cycle regulation (CDKN2A/B, RB1), and epi-
genetics (IDH1, IDH2, and BAP1, among others) (Table 1).
A worldwide consortium analyzing the genome of different tumors (the Cancer Genome Atlas) 
has recently revealed a comprehensive study of intrahepatic cholangiocarcinoma based on 
somatic mutations, RNA expression, copy number, and DNA methylation [34]. Similarly, inac-
tivating mutations have been found in tumor-suppressor genes, such as ARID1A, ARID1B, 
BAP1, TP53, and PTEN, and gain-of-function mutations have been found in the oncogenes, 
such as IDH1, IDH2, BRAF, and KRAS. Moreover, alterations in the regulation of the cell cycle 
have been reported: recurrent focal losses of CDKN2A, encoding p16INK4A, which inhibit the 
cyclin-dependent kinases CDK4 and CDK6, have been observed in 47% of the tumors.
6.2. Developing targeted therapies
Drugs targeting MAPK, FGFR, and IDH pathways have been developed widely in biliary 
duct carcinoma. One of the most prevalent alterations in cholangiocarcinoma is mutations in 
the proteins involved in RAF-MEK-ERK pathway. Targeting epithelial growth factor receptor 
Tumor subtype Alteration Targetable




Gallbladder carcinoma EFGR mutation Yes
ERBB2 mutation Yes
PTEN mutation Yes
ARID 1 mutation No
MLL2/MLL3 mutation No
TERT promoter mutation No
Extrahepatic cholangiocarcinoma PRKACA/B fusion Yes
ELF3 mutation No
ARID1B mutation No
Biliary duct common carcinoma TP53 mutation No
BRCA mutation Yes
PI3KCA mutation Yes
Table 1. Targeted therapies in biliary tract tumors.
Topics in the Surgery of the Biliary Tree64
(EGFR) as the first member of the MAPK pathway has not been successful. A phase III trial 
comparing platinum-based chemotherapy and gemcitabine with and without erlotinib did 
not show an improvement in progression-free survival [35]. Similar results were obtained 
with sorafenib (a multikinase inhibitor of RAF and VEGFR family) [36]. MET, a regulator of 
this pathway, can be inhibited by different drugs, such as tivantinib or cabozantinib. Despite 
preliminary efficacy of tivantinib combined with gemcitabine, cabozantinib (targeting MET 
and VEGFR2) showed limited activity [37–39].
KRAS mutation is observed in up to 25% of cholangiocarcinomas, and it has been associated 
to a worse prognosis in terms of progression-free survival and overall survival [40]. Targeting 
KRAS has been a challenge in oncology, and currently, there is not any available drug against 
it. However, it is possible to target downstream proteins, such as MEK. Selumetinib, an allo-
steric MEK inhibitor, was tested in advanced biliary cancer with good results as single ther-
apy in refractory setting (progression-free survival around 3 months and overall survival of 
9.7 months). This drug was also combined with standard first-line chemotherapy (cisplatin-
gemcitabine), but results were quite modest. Nevertheless, there was no selection according 
to KRAS mutation [41]. BRAF mutations are less prevalent, but results with therapies target-
ing this protein have shown better results.
For instance, in the vemurafenib basket trial (BRAF inhibitor in BRAF V600E mutant tumors), 
there was a partial response of eight patients treated with this drug [42]. However, there was 
up to 62% rate of disease control. Combinations of BRAF inhibitor and MEK inhibitor such as 
dabrafenib and trametinib are now being evaluated in clinical trials (NTC02034110).
Fibroblast growth factor receptor (FGFR) has been suggested as a potential target in cholan-
giocarcinoma, especially in intrahepatic cholangiocarcinoma with 20% of them showing any 
alteration. Most frequent alterations are fusions and mutations in FGFR2 and FGFR3. Some 
selective and nonselective small-molecule inhibitors of this receptor have been investigated in 
early phase clinical trials. Preliminary activity of oral pan-FGFR inhibitor BGJ398 has shown 
a disease-control rate of 82% in advanced cholangiocarcinoma in a phase II study, which is 
still recruiting (NCT02150967) [43]. Similarly, erdafitinib showed a 91% disease-control rate 
in this setting [44], and a phase II is ongoing to confirm these results. Derazantinib is another 
multikinase potent inhibitor, with a potent pan-FGFR inhibition. In the phase I trial [45], a 20% 
response rate was observed in FGFR-2 fusion-positive cholangiocarcinoma. Stable disease was 
observed in another 48% of the patients [45, 46]. TAS-120, Debio1347, and ponatinib are also 
drugs targeting FGFR in early phase I trials.
Other alterations in cholangiocarcinoma are ROS1 fusions with some interesting results with 
ALK/ROS inhibitors, such as ceritinib. Similarly, entrectinib (targeting not only ALK/ROS but 
also NTKR) has shown encouraging responses.
As previously described, alterations in IDH1, IDH2, BAP1, and ARID1A are frequently 
observed in cholangiocarcinoma. These genes are considered epigenetic regulators, as they 
are responsible for remodulating chromatin and histone regulation. Therefore, drugs target-
ing epigenetic alterations could be a strategy in biliary tract carcinoma. The most frequent 
mutated gene is IDH1, a gene that encodes isocitrate dehydrogenase, responsible among 
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 others, for the Krebs cycle or mitigating the oxidative stress. One of the most promising 
therapies is AG-120, a selective inhibitor of mutant IDH1. A 60% rate of disease control has 
been observed in a phase I trial. A phase III trial is now recruiting to confirm these results 
(NCT 02989857). Enasidenib is another IDH inhibitor, specific for IDH2 mutant tumors, 
which is currently being evaluated in another trial (NCT02273739). Other drugs that have 
been tested but without definitive results are histone deacetylase and DNA methyltransfer-
ase inhibitors.
7. Immunotherapy and cholangiocarcinomas
Treatment based on altering the immune response of the patient generating an intrinsic anti-
tumor effect is supposed to have a new change of paradigm in the field of medical oncology. 
Several tumors have seen their therapeutic arsenal expanded and have benefited from incred-
ible responses with a favorable toxic profile. It is a field in full scientific development, and 
poor prognosis tumors such as melanoma or nonsmall cell lung have been benefited.
Biliary tract tumors are infrequent tumors with low prevalence in Western Countries, which 
delay and complicate their recruitment in clinical studies. However, there are several clinical 
and biological characteristics of these tumors that make them attractive to the use of immu-
notherapy. These are tumors especially linked to chronic infection and inflammation pro-
cesses, similar to other tumors with good immune responses (i.e., HCC or head and neck 
carcinoma). These are tumors with a high rate of presentation of neoantigens associated with 
viral infection.
At least one subgroup of patients with cholangiocarcinoma has a high mutational load with 
abundant neoantigens and a high expression of immune-related genes, including inhibi-
tory-encoded genes. These are tumors with a poorer prognosis but with a good theoretical 
response profile to immunotherapy. New studies underway will delimit the role of these 
therapies in biliary tumors in the next few years. On the other hand, new therapies based on 
immune response are not exempt from possible high-risk secondary effects for these patients; 
cholangiocarcinomas often present a high risk of inflammatory life-threating complications 
(biliary stent, biliary superinfection).
8. Liquid biopsy: new steps toward better monitoring
Liquid biopsy (LqB) presents the possibility of detecting circulating tumor cells (CTCs) or 
small fragments of tumor DNA (cell-free DNA or cfDNA) in the circulatory system of patients, 
analyzing both primary tumors and metastases. This new technology has obvious advantages: 
it allows a global analysis of genetic changes in the global tumor mass, independently of the 
location of foci with independent genomic progression or novel mutations in isolated regions 
of the tumor tissue. LqB allows to study the tumor heterogeneity and to evaluate a dynamic 
tumor analysis over time, including the assessment of cancer-resistant subclone appearance, 
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and its results potentially predict the molecular dynamics associated with tumor response and 
drug resistance. Liquid biopsy monitoring of patients with cancer is a technically available 
procedure. However, our current knowledge should be expanded before it can be routinely 
implemented in daily clinical use.
Improvements have been made in technology, and there have been decreases in the response 
time and the costs of the procedure. In the near future, cancer research centers and even 
direct patient care centers will routinely request LqB for cancer patients using kits and genetic 
panels available. At this time, however, it is necessary to expand the available information 
about the LqB utility, especially the clinical interpretation of its results and limitations of the 
technique. Unfortunately, at this time, there are no studies that validate its usefulness in bile 
duct tumors.
9. Conclusions: multimodality approach
At present, we are witnessing some exciting changes in the clinical management of tumors 
of the biliary tract. Primarily, the development of new radiological techniques allows an 
earlier and more accurate diagnosis of these diseases; they also provide many anatomic and 
functional relevant information with a prognostic value. A critical advancement in nearly all 
of extrahepatic bile duct tumor management is the improvement in interventional radiology 
techniques, especially biliary stents in locally advanced disease. Their staging has improved 
a better global approach and more accurate prognostic allocation. The emergence of more 
accurate radiotherapy treatments can expand the indications of the most novel techniques, 
such as IMRT, in the near future. Standard chemotherapy regimens, although still with 
discrete results in advanced disease in terms of survival, allow the comparison with other 
Figure 2. Multimodality approach in patients with biliary tract tumors.
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novel treatments. Finally, the advancement in molecular knowledge is critical to understand 
the pathogenesis and for the development of new treatments directed against therapeutic 
targets.
However, the most important step yet for advancing the treatment of these complex diseases 
is the appearance of multidisciplinary management teams focusing on patient treatment 
in a comprehensive approach. It is critical for the development of new strategies to assess 
each case from the point of view of multiple specialists in reference centers that can integrate 
the careful work of qualified specialists. Similarly, the most appropriate treatment should 
respond to the variable disease evolution of each patient, both in the curative approach and in 
the advanced disease of worse prognosis.
Finally, it is very important to remember, as shown in Figure 2, that the treatment of a tumor 
as aggressive as cholangiocarcinoma in a patient needs the participation and use of psycho-
logical, spiritual, social, family, voluntary, economic, that should be considered in each center 
of each specific region, resources that exceed the realization of this article. Unfortunately, the 
current advances have not translated into a change in the natural history of these diseases.
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